Your browser doesn't support javascript.
loading
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz, Michael D; Cappato, Riccardo; Klein, Allan L; Camm, A John; Ma, Chang-Sheng; Le Heuzey, Jean-Yves; Talajic, Mario; Scanavacca, Maurício I; Vardas, Panos E; Kirchhof, Paulus; Hohnloser, Stefan H; Hemmrich, Melanie; Lanius, Vivian; Meng, Isabelle Ling; Wildgoose, Peter; van Eickels, Martin.
Afiliação
  • Ezekowitz MD; Cardiovascular Research Foundation, New York, NY; Jefferson Medical College, Philadelphia, PA.
  • Cappato R; Arrhythmia and Electrophysiology Center, University of Milan, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; Department of Cardiology, Heraklion University Hospital, Heraklion (Crete), Greece.
  • Klein AL; Department of Cardiovascular Medicine, Cleveland Clinic Heart and Vascular Institute, Cleveland, OH.
  • Camm AJ; Division of Clinical Sciences, St George's, University of London, London, United Kingdom.
  • Ma CS; Cardiology Division, Beijing AnZhen Hospital, Capital Medical University, Beijing, China.
  • Le Heuzey JY; Division of Cardiology and Arrhythmology, Hôpital Européen Georges Pompidou, Université Paris V René-Descartes, Paris, France.
  • Talajic M; Department of Medicine, Research Center, Montreal Heart Institute, Université de Montréal, Montreal, Canada.
  • Scanavacca MI; Arrhythmia Clinical Unit of Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
  • Vardas PE; Department of Cardiology, Heraklion University Hospital, Heraklion (Crete), Greece.
  • Kirchhof P; University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Department of Cardiology and Angiology, University Hospital Münster, Münster, Germany.
  • Hohnloser SH; Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, Frankfurt, Germany.
  • Hemmrich M; Global Clinical Development, Bayer Vital GmbH, Leverkusen, Germany.
  • Lanius V; Global Research and Development Statistics, Bayer HealthCare, Berlin, Germany.
  • Meng IL; Global Medical Affairs, Bayer HealthCare, Berlin, Germany.
  • Wildgoose P; Janssen Scientific Affairs, LLC, Raritan, NJ.
  • van Eickels M; Global Medical Affairs, Bayer HealthCare, Berlin, Germany.
Am Heart J ; 167(5): 646-52, 2014 May.
Article em En | MEDLINE | ID: mdl-24766973
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Tiofenos / Vitamina K / Cardioversão Elétrica / Morfolinas / Embolia Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Am Heart J Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Panamá País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Tiofenos / Vitamina K / Cardioversão Elétrica / Morfolinas / Embolia Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Am Heart J Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Panamá País de publicação: Estados Unidos